Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Aug 25, 2023 (3 years ago)

Digoxin Tablets

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Digoxin Tablets, USP 0.125mg, 100-count bottles, Rx Only, Manufactured for/Distributed by: Marlex Pharmaceuticals, Inc. New Castle, DE NDC# 10135-0747-01

Affected NDC 10135-0747-01

Compare with the code on your package — it is the most precise check available.

Drug: Digoxin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Digoxin
NDC 10135-0747
.125 mg/1 Tablet
Oral
Marlex Pharmaceuticals, Inc. Rx
Recalling firm
Marlex Pharmaceuticals, Inc.
NDC code
10135-0747-01
Origin
DE, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Aug 30, 2023 · FDA notice with lot numbers
FDA recall number
D-1169-2023 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Digoxin recalls

See all
Class III · Low risk

Digoxin Tablets

Cross Contamination with Other Products:(mycophenolate mofetil).

Terminated Cross-contamination Novitium Pharma LLC NDC 70954-201-20 D-0389-2024
Class II · Moderate risk

Digoxin Tablets

Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

Terminated Labeling / mix-up Marlex Pharmaceuticals, Inc. NDC 10135-0748-01 D-1170-2023
Class II · Moderate risk

Digoxin

Labeling: Label Mixup: DIGOXIN, Tablet, 125 mcg may have potentially been mislabeled as the following drug: CHOLECALCIFEROL/ CALCIUM/ PHOSPHORUS, Tablet, 120 units/105 mg/81 mg, NDC 64980015001, Pedigree: W002581, EXP: 6/3/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-919-2014

Other recalls by Marlex Pharmaceuticals, Inc.

All 2023 recalls
Class II · Moderate risk

Digoxin Tablets

Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

Terminated Labeling / mix-up Marlex Pharmaceuticals, Inc. NDC 10135-0748-01 D-1170-2023
Class II · Moderate risk

Acetaminophen Tablets

CGMP Deviations: The recalled acetaminophen tablet lot was not manufactured under current good manufacturing practices as noted by a recent inspection of the manufacturing firm.

Terminated cGMP deviation Marlex Pharmaceuticals, Inc. NDC 10135-152-01 D-1064-2013